-
Castleman's disease (CD), angiofollicular lymph- node hyperplasia, was initially described a half century ago in asymptomatic patients with a mediastinal mass.
-
Imatinib results in significant and durable responses for CML. The safety of discontinuation has not been rigorously tested. In a prospective study, imatinib was discontinued among CML patients in a complete molecular remission (CMR) for 2 years or more. Among 69 patients with at least one year of follow-up, 61% relapsed by molecular analysis, almost all by 6 months. After imatinib reintroduction, all 42 relapsing patients responded, of which 26 (62%) entered CMR again. High Sokal score at baseline, female sex, and shorter period of CMR predicted for relapse on imatinib discontinuation. Around 40% of patients with CML in prolonged CMR on imatinib do not relapse at least one year after stopping the drug.
-
A55-year-old woman presents to her primary physician with worsening diarrhea and abdominal discomfort. Symptoms first occurred 3 months prior to presentation, and were mild.
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
Extubation is defined as removal of the endotracheal tube. The decision to extubate is usually based on three considerations: 1) need for invasive respiratory support; 2) patency of the upper airway; and 3) ability to clear secretions from the lower respiratory tract.
-
-
-
Intensive care unit (ICU) survivors experience various morbidities that can limit long-term recovery. One of the most common problems, neuromuscular weakness, has been
-
Carried out in four ICUs in the Netherlands, this study evaluated the effects of a serum lactate-guided resuscitation protocol during initial management of critically ill patients with elevated lactate levels, as compared to standard management not guided by serial lactate measurements.
-
In a year when belt-tightening seemed to be a national pastime, about 35% of participants in the Contraceptive Technology Update Salary Survey reported a 1-3% uptick in salary, with 43% seeing no change in pay levels.